The term translational research often refers to the process “bench-to-bedside” implying that knowledge from basic sciences can be applied to produce new drugs, devices and treatments. However, it can also refer to translation of early human research into practice; i.e., ensuring that new knowledge reaches the patients or populations for whom they are intended. Thus, two very different translational blocks have been identified: T1 - the transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention. T2 - the translation of results from clinical studies into everyday clinical practice and health decision making. The present round table discussion will focus on why many of our efforts to apply these concepts have failed and what can be done to improve our approach.
|13:30||13:40||The translational impact of preclinical models for LUT dysfunction||Lori Birder|
|13:43||13:53||Continence drugs for the future||Karl-Erik Andersson|
|13:56||14:06||Clinical Pharmacology in translational research||Thomas Hedner|
|14:09||14:19||Translational research from drug industry perspective||Eboo Versi|